Total Soluble and Endogenous Secretory Receptor for Advanced Glycation End Products as Predictive Biomarkers of Coronary Heart Disease Risk in Patients With Type 2 Diabetes
Helen M. Colhoun(Edinburgh Cancer Research), John Fuller(The Royal Free Hospital), Kathryn Choon Beng Tan(Queen Mary Hospital), David A. DeMicco(Pfizer (United States)), Valentine Charlton-Menys(Manchester Royal Infirmary), Weihang Bao(Tulane University), Paul N. Durrington(University of Manchester), Harshal Deshmukh(University of Dundee), Andrew Neil(University of Oxford), D. J. Betteridge, Gregory M. Preston(Pfizer (United States)), G. A. Hitman, Shona Livingstone(University College London)
Cited by 162
Related Papers
Association between Multiple Cardiovascular Risk Factors and Atherosclerosis in Children and Young Adults
|New England Journal of Medicine|1998|4k
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
|The Lancet|2004|3.8k
ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
|European Heart Journal|2011|3.5k
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
|New England Journal of Medicine|2023|2.6k
Vascular Risk Factors and Diabetic Neuropathy
|New England Journal of Medicine|2005|1.3k